TY - JOUR
T1 - International exchange on the clinical practice and research of rheumatic skin diseases
T2 - A report of the 5th International Conference of Cutaneous Lupus Erythematosus
AU - Hasegawa, Minoru
AU - Chasset, François
AU - Chong, Benjamin F.
AU - Fiorentino, David F.
AU - Fujimoto, Manabu
AU - Nyberg, Filippa
AU - Sato, Shinichi
AU - Wenzel, Joerg
AU - Werth, Victoria P.
N1 - Publisher Copyright:
© 2024 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.
PY - 2024
Y1 - 2024
N2 - The 5th International Conference of Cutaneous Lupus Erythematosus was held in Tokyo, Japan on May 9 and 10, 2023. The latest topics on the pathogenesis, diagnosis, assessment, and treatment of cutaneous lupus erythematosus, dermatomyositis, and scleroderma (systemic sclerosis, morphea) were presented by experts in each field and new developments discussed. In these rheumatic skin diseases, many clinical trials of novel therapies targeting cytokines, signaling molecules, plasmacytoid dendritic cells, B cells, and other molecules are currently underway, and standardization of outcome assessment was discussed. In addition, the selection of the therapeutic agents available for the diversity of each case is becoming more important, together with the ongoing pathophysiological analysis of the diseases. The achievements of this conference will further promote the development of clinical practice and research in rheumatic skin diseases through international exchange among researchers. We hope that by reporting a summary of the conference in this manuscript, we can share its contents with readers.
AB - The 5th International Conference of Cutaneous Lupus Erythematosus was held in Tokyo, Japan on May 9 and 10, 2023. The latest topics on the pathogenesis, diagnosis, assessment, and treatment of cutaneous lupus erythematosus, dermatomyositis, and scleroderma (systemic sclerosis, morphea) were presented by experts in each field and new developments discussed. In these rheumatic skin diseases, many clinical trials of novel therapies targeting cytokines, signaling molecules, plasmacytoid dendritic cells, B cells, and other molecules are currently underway, and standardization of outcome assessment was discussed. In addition, the selection of the therapeutic agents available for the diversity of each case is becoming more important, together with the ongoing pathophysiological analysis of the diseases. The achievements of this conference will further promote the development of clinical practice and research in rheumatic skin diseases through international exchange among researchers. We hope that by reporting a summary of the conference in this manuscript, we can share its contents with readers.
UR - http://www.scopus.com/inward/record.url?scp=85187169960&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85187169960&partnerID=8YFLogxK
U2 - 10.1111/1346-8138.17153
DO - 10.1111/1346-8138.17153
M3 - Article
C2 - 38450816
AN - SCOPUS:85187169960
SN - 0385-2407
JO - Journal of Dermatology
JF - Journal of Dermatology
ER -